# TQT2 Study to Evaluate the Effect of MD1003 on Cardiac Repolarization in Healthy Adult Subjects

> **NCT04168723** · PHASE1 · UNKNOWN · sponsor: **MedDay Pharmaceuticals SA** · enrollment: 64 (estimated)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** MD1003
- **DRUG:** Moxifloxacin 400mg
- **DRUG:** Placebo for MD1003
- **DRUG:** Placebo for moxifloxacin

## Key facts

- **NCT ID:** NCT04168723
- **Lead sponsor:** MedDay Pharmaceuticals SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-11
- **Primary completion:** 2020-03-05
- **Final completion:** 2020-03-05
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2020-02-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04168723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04168723, "TQT2 Study to Evaluate the Effect of MD1003 on Cardiac Repolarization in Healthy Adult Subjects". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04168723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*